Abstract
Apoptosis is a programmed cell death process, critical for normal cellular development and tissue homeostasis. B-cell lymphocyte/leukemia 2 (Bcl-2) family proteins are important regulators of apoptosis. Numerous studies have demonstrated that over-expressing anti-apoptotic Bcl-2 proteins is one mechanism for cancer cells to acquire resistance against cancer chemotherapies, suggesting antagonizing these proteins would be a potential approach to overcoming such drug resistance. This review briefly discusses the principle and the recent advances in the development of such antagonists, with some highlights about several promising antagonists.
| Original language | English (US) |
|---|---|
| Pages (from-to) | 171-178 |
| Number of pages | 8 |
| Journal | Mini-Reviews in Organic Chemistry |
| Volume | 5 |
| Issue number | 3 |
| DOIs | |
| State | Published - 2008 |
Keywords
- Apoptosis
- Bcl-2 antagonists
- Cancer
- Drug resistance
